A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature
Authors:
- 6 July 2015
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Abstract
There are only three cases in the literature that describe development of neurosarcoidosis in a patient who is on tumour necrosis factor α inhibitors. We describe a case of a 33-year-old woman with a history of juvenile rheumatoid arthritis and refractory uveitis (with previous treatment trials of adalimumab, infliximab, mycophenolate, methotrexate) who had been stable for 2 years on etanercept. She was diagnosed with biopsy-proven systemic sarcoidosis with meningeal and parenchymal neurosarcoidosis. She was switched to infliximab and methotrexate, with clinical and imaging improvements. This is a case that demonstrates the difficulty of choosing tumour necrosis factor α (TNF-α) inhibitors when treating patients with multiple clinical autoimmune entities. It is also a case where a change in the mechanism of TNF-α inhibition pathway can still be used to treat refractory sarcoidoisis and rheumatoid arthritis. It is still unclear what the exact difference between the TNF-α blockers and their neurological complications is, and who the patients at risk of developing neurological complications are.Keywords
This publication has 15 references indexed in Scilit:
- Neurologic manifestations of sarcoidosis2014
- Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritisBMC Neurology, 2013
- Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitorsJournal of Neurology, 2013
- New onset sarcoid‐like granulomatosis developing during anti‐TNF therapy: an under‐recognised complicationInternal Medicine Journal, 2011
- Dramatic response to infliximab in refractory neurosarcoidosisAnnals of Indian Academy of Neurology, 2010
- The Immunology of SarcoidosisClinics in Chest Medicine, 2008
- Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab.2007
- Tumour necrosis factor α inhibitors in the treatment of childhood uveitisRheumatology, 2006
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- Central nervous system sarcoidosisdiagnosis and managementQJM: An International Journal of Medicine, 1999